News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexo AB Provides Update on Simplified Market Situation for Zubsolv™ (OX219) in United States



9/25/2012 10:07:26 AM

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: The Swedish specialty pharmaceutical company Orexo AB (STO:ORX) today announce a major change in the competitive landscape for Zubsolv™, its treatment of opioid dependence, which has been submitted and currently is undergoing review at the FDA. Reckitt Benckiser Ltd announced this morning a voluntary discontinuation of the supply of Suboxone® tablets in United States, which currently account for approximately 35% of the US market.

Read at BioSpace.com


comments powered by Disqus
Orexo AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES